Literature DB >> 8009858

HIV-2 EHO isolate has a divergent envelope gene and induces single cell killing by apoptosis.

M A Rey-Cuille1, J Galabru, A Laurent-Crawford, B Krust, L Montagnier, A G Hovanessian.   

Abstract

The human immunodeficiency virus type 2 (HIV-2)-related isolate, referred to as HIV-2 EHO, has been isolated from an Ivory Coast patient with acquired immunodeficiency syndrome (AIDS). Infection of CD4 expressing cells with this highly infectious virus mediates a cytopathic effect characterized by single-cell killing as a consequence of apoptosis. Nucleotide sequence analysis of the HIV-2 EHO genome revealed a significant degree of divergence of its envelope gene from that of other known HIV-2 strains. This divergence for the deduced amino acid sequence corresponding to the extracellular envelope glycoprotein was 26 to 30%. These unique genetic and biological properties suggest that the HIV-2 EHO isolate is a distinct prototype in the HIV-2 family.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8009858     DOI： 10.1006/viro.1994.1364

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  11 in total

1.  JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

Authors:  K Yoshimura; R Kato; K Yusa; M F Kavlick; V Maroun; A Nguyen; T Mimoto; T Ueno; M Shintani; J Falloon; H Masur; H Hayashi; J Erickson; H Mitsuya
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

2.  Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41.

Authors:  B Labrosse; O Pleskoff; N Sol; C Jones; Y Hénin; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

3.  Usage of the coreceptors CCR-5, CCR-3, and CXCR-4 by primary and cell line-adapted human immunodeficiency virus type 2.

Authors:  N Sol; F Ferchal; J Braun; O Pleskoff; C Tréboute; I Ansart; M Alizon
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Possible role of the V3 domain of gp120 in resistance to an amphotericin B derivative (MS8209) blocking human immunodeficiency virus entry.

Authors:  O Pleskoff; N Sol; H Marrakchi; M Serlin; M Seman; M Alizon
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

5.  Loss of CD4+ T cells in human immunodeficiency virus type 1-infected chimpanzees is associated with increased lymphocyte apoptosis.

Authors:  I C Davis; M Girard; P N Fultz
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

6.  Alphavirus-induced apoptosis in mouse brains correlates with neurovirulence.

Authors:  J Lewis; S L Wesselingh; D E Griffin; J M Hardwick
Journal:  J Virol       Date:  1996-03       Impact factor: 5.103

7.  A rationally engineered anti-HIV peptide fusion inhibitor with greatly reduced immunogenicity.

Authors:  Frances Brauer; Kerstin Schmidt; Roland C Zahn; Cornelia Richter; Heinfried H Radeke; Jörn E Schmitz; Dorothee von Laer; Lisa Egerer
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

8.  Rapid shift from virally infected cells to germinal center-retained virus after HIV-2 infection of macaques.

Authors:  F Eitner; Y Cui; G Grouard-Vogel; K L Hudkins; A Schmidt; T Birkebak; M B Agy; S L Hu; W R Morton; D M Anderson; E A Clark; C E Alpers
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

9.  Adaptation of chimeric retroviruses in vitro and in vivo: isolation of avian retroviral vectors with extended host range.

Authors:  E V Barsov; W S Payne; S H Hughes
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

10.  A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site.

Authors:  Kazuhisa Yoshimura; Ryohei Kato; Mark F Kavlick; Aline Nguyen; Victor Maroun; Kenji Maeda; Khaja A Hussain; Arun K Ghosh; Sergei V Gulnik; John W Erickson; Hiroaki Mitsuya
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.